- Home
- News Centre Resources
- Shortening the Path to Diagnosis in Rare Disease
Shortening the Path to Diagnosis in Rare Disease

With 10,000 known rare diseases defined today, the path to diagnosis can often resemble a puzzle, with physicians as detectives searching for clues. Many physicians never encounter a rare disease beyond the pages of their medical school textbooks. Moreover, many symptoms can be varied and non-specific, which can lead to a time-consuming process of excluding more common diseases.
These complexities can further delay answers and place a heavy burden on patients and caregivers, as they endure a multitude of tests and appointments in search of an accurate diagnosis. This quest can place a strain on families and add expenses, requiring long-distance travel for specialist visits, missed workdays and childcare. This experience, referred to as the diagnostic odyssey, is often marked by frustration, misdiagnosis and prolonged uncertainty–and it is far too common within the rare disease community.
Watch the video to hear more from Alexion’s R&D leaders about promising areas of diagnostic innovation that are bringing new hope to millions of people impacted by rare diseases.

Fortunately, there is momentum building around efforts to shorten the diagnostic odyssey. Promising developments are being made to use genetic testing to accelerate accurate diagnosis, particularly as it relates to children, who make up 50% of rare disease patients. By identifying rare diseases early in life through blood test-based newborn screening, families and physicians may have new tools to help make better-informed decisions about a child’s treatment plan, including eligibility for clinical trials when approved treatments may not yet exist.
Advanced analytics tools, such as machine learning and artificial intelligence, also hold promise. These technologies are making it possible for physicians to interpret existing rare disease health information and diagnostic criteria more rapidly, which may allow them to reach answers faster. With the help of these powerful algorithms, industry, academia and health systems are identifying new ways to diagnose rare diseases sooner.
By harnessing these technologies and broadening access to them for diagnostics, we have the potential to create better outcomes for children and their families and a more sustainable and equitable healthcare system.
Share This Page
More articles you may like
Article • February 24, 2025
Supporting Patients on Rare Disease Day, and Every Day
Rare Disease Day recognizes the 400 million people worldwide – and 30 million in the United States – who are living with a rare disease. While significant progress has been made in understanding rare diseases and developing treatments, the need for continued awareness, research and support is as great as ever.
Patient Support • February 05, 2025
Addressing the Unmet Needs of the Amyloidosis Community
We spoke with Cristina Quarta, Executive Medical Director, about a group of rare diseases known as amyloidosis, the medical needs within this community and how her work as a cardiologist shapes her approach to research and development (R&D) for rare cardiac conditions.
Research and Development • September 18, 2024
Getting to know Nick France, an Alexion R&D Leading Voice
To create meaningful advances in rare disease research, it takes an innovative culture, strong collaboration, and a patient-centric vision for delivering transformational solutions. At Alexion, these pillars are important to successfully develop impactful medicines for patients.
Patient Support • June 25, 2024
Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice
Artificial Intelligence (AI) is rapidly advancing and has the potential to have a transformative impact on clinical research and development (R&D).
Research and Development • June 08, 2024
Getting to know Seng Cheng, an Alexion R&D Leading Voice
There is a sense of urgency that underlies research in rare diseases, because these diseases are often rapidly progressive.
Patient Support • April 18, 2024
Getting to know Sophia Zilber, Associate Director, Statistical Programming
The voices and perspectives of patients play an essential role in rare disease research and development (R&D).
Patient Support • April 16, 2024
Getting to know Banu Sankaran, an Alexion R&D Leading Voice
Diagnostics and artificial intelligence (AI) systems are transforming research and development (R&D) in the healthcare industry.
Health Equity • February 06, 2024
Driving health equity for the rare disease community
Collectively, more than 400 million people around the world are living with a rare disease, defined as conditions that affect a small number of people compared to the general population.
Patient Support • November 08, 2023
Getting to Know Mary Kunjappu, an Alexion R&D Leading Voice
Science is hard, but rare disease research and development (R&D) stands apart. Because individual patient populations are small and many rare diseases are not well understood, research in this space can often bring added complexity.
Veeva ID: US/NP/0064